BTIG raises target to USD 26 for Cryoport stock

Published on 10/20/2026 at 20:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cryoport plans Santa Ana and Paris facilities in the second half of 2026. Cryoport stock costs EUR 15.30 at Lang & Schwarz on October 20, 2026.

BTIG target lifted

BTIG raised its Cryoport target from USD 25.00 to USD 26.00 on October 13, 2026.
Cryoport plans facilities or services in Santa Ana and Paris during the second half of 2026.
Cryoport stock costs EUR 15.30 at Lang & Schwarz on October 20, 2026 at 8:33 p.m. CEST.
Second-quarter adjusted EBITDA reached USD 0.40 million, while full-year revenue guidance stood at USD 192.00 million to USD 196.00 million.

CYRX, US2290503075, Illustration mit AI erstellt.

Cryoport (US2290503075) received a higher USD 26.00 price target from BTIG on October 13, 2026, up from USD 25.00, while the firm kept its Buy rating, as Investing.com reported. The USD 26.00 target lies 51.08 percent above the Nasdaq price of USD 17.21 on October 20, 2026. Cryoport stock was trading at EUR 15.30 at Lang & Schwarz on October 20, 2026 at 8:33 p.m. CEST.

BTIG links growth to expansion

BTIG based its revised view on meetings with Cryoport executives and a site visit, according to Markets Insider. The company plans to open new facilities or services in Santa Ana, California, and Paris, France, during the second half of 2026. BTIG expects revenue growth and positive EBITDA during that period.

Nasdaq price stays below yearly high

On the Nasdaq, Cryoport last traded at USD 17.21 on October 20, 2026 at 2:37 p.m. ET while the session was open. The quote stood USD 1.15 below the 52-week high of USD 18.36 and USD 9.60 above the 52-week low of USD 7.61. The market capitalization was USD 871.8 million, and the trailing P/E ratio was negative 21.00.

Second-quarter figures set the baseline

Cryoport identifies the second quarter of 2026 as its latest reported period, ended June 30, 2026. In that quarter, the company generated USD 49.00 million of revenue and adjusted EBITDA of USD 0.40 million, according to Investing.com. Full-year revenue guidance remained USD 192.00 million to USD 196.00 million.

What the target implies

The BTIG target places the expansion story ahead of the current Nasdaq quotation, but the company still reports a negative trailing P/E ratio. For investors, the key comparison is therefore between the projected facility rollout, the USD 192.00 million to USD 196.00 million revenue range and the latest adjusted EBITDA result.

Price and operating outlook

Cryoport's platform covers biopharmaceutical logistics, storage, processing and cryogenic systems across the Americas, EMEA and APAC, according to its investor-relations page. The company lists 50 strategic locations, giving the Santa Ana and Paris plans a direct connection to its existing operating footprint. The Nasdaq price and BTIG target remain the clearest near-term market measures for the stock.

The further course of trading is shown by the continuously updated real-time quote of Cryoport stock.